Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria
Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria
复制标题
DOI：
10.1080/03630269.2019.1649278
复制
发表时间：
2019-08-28
期刊：
影响因子：
1
通讯作者：
Adekile, Adekunle D.
中科院分区：
文献类型：
--
作者：
Adeyemo, Titilope A.;Diaku-Akinwunmi, Ijeoma N.;Adekile, Adekunle D.
羟基脲（HU）是一种众所周知的Hb F诱导剂，已证实对镰状细胞病患者具有临床和实验室疗效。然而，对其长期安全性和毒性的担忧限制了医生的处方和患者的可接受性。因此，本研究旨在评估临床医生在尼日利亚镰状细胞病患者管理中使用HU的障碍。一项针对尼日利亚儿科、血液学、内科、家庭医学和一般医疗实践中管理镰状细胞病的医生的在线调查。调查分为四个部分：人口统计、使用HU的知识和经验以及使用HU的障碍。123名联系人中有91人（73.0%）完成了调查。73%和74.0%的受访者分别指出HU降低了输血率和改善了患者的整体生活质量（QOL）。虽然大多数从业者（55.6%）每月看10-50名患者，但大多数（66.7%）
Hydroxyurea (HU) is a well-known Hb F-inducing agent with proven clinical and laboratory efficacy for patients with sickle cell disease. However, concerns about its long-term safety and toxicity have limited its prescription by physicians and acceptability by patients. Thus, this study aims to evaluate clinician's barriers to the use of HU in the management of patients with sickle cell disease in Nigeria. An online survey targeted physicians in pediatrics, hematology, medicine, family medicine and general medical practice managing sickle cell disease in Nigeria. The survey was in four sections: demographic, knowledge and experience with HU, and barriers to the use of HU. Ninety-one (73.0%) of 123 contacts completed the survey. Seventy-three percent and 74.0% of the respondents noted that HU reduced transfusion rates and improved overall quality of life (QOL) of patients, respectively. While the majority of the practitioners (55.6%) see between 10-50 patients per month, most (66.7%) write